In late October 2025, Chloroform markets turned out to be broadly stable worldwide, indicating a balance between supply and demand following months of price decline. The U.S., South Korea, and Europe remained steady, supported by steady production, sufficient stocks and normal trading activity. Participants described sentiment throughout the industry as neutral with limited arbitrage activity and normal operations for plants. In contrast, China remained under downward pressure as demand from the pharmaceutical and refrigerant industries was weak and high domestic production curbed imports. Demand for the refrigerant R22, a major downstream product of chloroform, declined due to the end of the hot weather season. Overall, the Chloroform market remained steady in the West, but soft in China, indicating range bound conditions into November.
